




Roche Collaboration

October 20, 2022


This presentation and other related material may contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding HOOKIPA’s expectation about any or all of the following: (i) the success, cost and timing of HOOKIPA’s product development activities and clinical trials; (ii) the timing, scope or likelihood of regulatory filings and approvals, including timing of Investigational New Drug Application and Biological Licensing Application filings for HOOKIPA’s current and future product candidates, and final U.S. Food and Drug Administration, European Medicines Agency or other foreign regulatory authority approval of HOOKIPA’s current and future product candidates; (iii) HOOKIPA’s ability to develop and advance its current product candidates and programs into, and successfully complete, clinical studies; (iv) the potential benefits of and HOOKIPA’s ability to maintain its collaboration with Gilead Sciences, Inc., and establish or maintain future collaborations or strategic relationships or obtain additional funding; (v) risks relating to business interruptions resulting from the coronavirus (COVID-19) disease outbreak or similar public health crises and other matters that could affect the sufficiency of existing cash to fund operations and HOOKIPA’s ability to achieve the milestones under the agreement with Gilead. Forward-looking statements can be identified by terms such as “believes,” “expects,” “plans,” “potential,” “would” or similar expressions and the negative of those terms HOOKIPA has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Although HOOKIPA believes that such statements are based on reasonable assumptions, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond HOOKIPA’s control, you should not rely on these forward-looking statements as predictions of future events. These risks and uncertainties include, among others: outcomes of HOOKIPA’s planned clinical trials and studies may not be favorable; that one or more of HOOKIPA’s product candidate programs will not proceed as planned for technical, scientific or commercial reasons; availability and timing of results from preclinical studies and clinical trials; uncertainty about regulatory approval to conduct clinical trials or to market a products; uncertainties regarding intellectual property protection; and those risk and uncertainties described under the heading “Risk Factors” in HOOKIPA’s Form 10-Q for the quarter ended June 30, 2022 filed with the U.S. Securities and Exchange Commission, and in any other subsequent filings made by HOOKIPA with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Existing and prospectus investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. HOOKIPA disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this presentation, other than to the extent required by law.

Strategic Collaboration with Roche: Strong Validation of HOOKIPA's Arenavirus Platform in Oncology and Acceleration of Pipeline Expansion



- License for HOOKIPA's HB-700 KRAS program and option for a second undisclosed arenaviral immunotherapy
- \$25m upfront, \$930m potential success-based payments for both programs plus tiered royalties
- HB-700 is designed to target multiple KRAS mutations simultaneously to cover lung, colorectal, pancreatic, and other cancers
- HOOKIPA to conduct preclinical development, IND preparation and early clinical development; handover to Roche after Phase 1b

HOOKIPA's Arenaviral Platform Ideally Suited to Induce Strong Specific CD8⁺ T Cell Responses Against KRAS-Mutated Tumor Cells



Direct measurement without prior in vitro expansion of cells; majority of patients show peak responses 2-3 weeks post first administration.

Fast and durable induction of active tumor-specific T cell responses in nearly all patients:

- ~80% of patients have measurable tumor specific T cell response after first administration
- ~90% of patients have measurable T cell response after second, third and fourth administrations

KRAS

- KRAS is a gene that acts as an on/off switch for cell growth
- **KRAS mutations are among the most common mutations that cause cancer¹**

Prevalence

- **≥ 80% in pancreatic²**
- **~30% in colorectal²**
- **15-20% in lung²**
- Prevalent in many other cancer types

Market Potential


- One product candidate targeting five most prevalent KRAS mutations in multiple indications¹
- 2021: **≥ 200,000 patients** in the US and EU who could have benefited in just the pancreatic, colorectal, and lung indications³

¹Nature Reviews Clini Onc (2022) 19 637-655; ²Cancer Res (2020) 80 (14); 2969-2974; COSMIC database; ³Internally sourced reports.


HB-700: One Product Encoding the Five Most Prevalent Mutations Relevant for 74% - 95% of KRAS-Mutated Pancreatic, Colorectal, and Lung Cancers




Pancreatic



Colorectal



Lung



G12D - G12V - G12C - G12R - G13D

Analysis provided by Catenion.

Roche Collaboration: \$25m Upfront, Up to ~\$930m in Future Milestones Plus Royalties



License for HB-700 KRAS program and option for a second undisclosed arenaviral immunotherapy

Development Path

Preclinical

- HOOKIPA responsible for all preclinical development
- Roche milestone payments

Phase 1b

- HOOKIPA responsible for Phase 1b trial
- 50/50 cost-sharing
- Roche IND related milestone payments

Further development

- Roche responsible for all further R&D, manufacturing and commercialization; Roche funds all
- Hookipa entitled to receive milestone payments

Financial Terms


Total of \$955m in upfront and milestones




HB-700 KRAS mutant therapy

- R&D and commercial milestones
- Tiered royalties: high single-digit to mid-teens %

Undisclosed novel arenaviral therapy

- \$15m at option exercise
- R&D and commercial milestones
- Tiered royalties: high single-digit to mid-teens %



- 1 Off-the-shelf *in vivo* T cell technology; robust PoC of T cell mechanism
- 2 HB-200 Phase 2 progressing in combination with pembrolizumab in 1L and 2L settings and as stand-alone therapy in post-SOC setting
- 3 Expanding pipeline: HB-300 Phase 1 FPI in Q1 2023
- 4 **Strong partnership validation:**   GILEAD  MERCK
- 5 June 30 *pro forma* cash position: **\$144m**
(\$119m cash¹ + \$25m Roche upfront) additionally \$30m Gilead facility

PoC, proof of concept; 1L/2L, line of therapy; SOC, standard of care; FPI, first patient in.

¹June 30 cash position \$119m.

HB-200
HPV16+
HNSCC

HB-200 + Pembro Combination

- Phase 2 1L Initial Data: **2H 2022**
- Phase 2 2L+ Initial Data: **2H 2022**



MERCK Randomized Phase 2 1L start: **1H 2023**
(Fast Track Designation; 100% rights with Hookipa)

Post-SOC HB-200 Alone Phase 2 Data: 1H 2023

HB-300

Prostate Cancer FPI: **1Q 2023**

HB-700



KRAS Mutations IND



GILEAD Hepatitis B IND: **2022**



GILEAD HIV IND: **2023**

HBV & HIV



HOOKIPA
PHARMA